ClinicalTrials.gg
RecruitingNCT07056244Updated Aug 11, 2025

Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Caudal Epidural Block

An interventional study of Dexmedetomidine and Dexamethasone in İnguinal Hernia, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 2 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Sohag University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
2 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernia, Inguinal with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Hernia, Inguinal · Egypt.

Planned enrollment
11th of 43
80 · median 60
Started
2025
with 3 others
No phase
38 of 45
14 open now
Primary completion
2025-12
later than 9 of 16 live
Registered
32nd of 45
by date
Lead sponsor
6 of 45
Sohag University

Among the 45 studies in Hernia, Inguinal with a site in Egypt, this one is the 11th largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2025, is one of 38 with no phase, reaches primary completion later than 9 of the 16 other live ones, and was the 32nd registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

16 of the 45 studies in Hernia, Inguinal with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 2 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernia, Inguinal with a site in Egypt, or all of them as a file.
02

Study summary

The goal of This prospective, randomized, double-blind comparative study is to compare the efficacy of dexamethasone and dexmedetomidine as adjuvants to bupivacaine 0.125% in caudal epidural block for pediatrics undergoing inguinal hernia surgery, aged 2-6 years.

of Both sex.

03

Conditions studied

  • İnguinal Hernia

Browse trials for

04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 2-6 years.
  • Both sexes.
  • (ASA) physical status I and II.
  • Scheduled for inguinal hernia surgery

Exclusion criteria

Exclusion Criteria:

  • Parents or legal guardians refusal.
  • Known to any study drugs.
  • Abnormal sacral anatomy
  • Local infection at the injection site.
  • Neurological disease.
  • Coagulopathy.
  • Mental retardation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    group A will receive Bupivacaine + Dexmedetomidine

    Patients will receive Bupivacaine 0.125% at 0.5 ml/kg + Dexmedetomidine 1.5 mcg/kg for post operative analgesia.

    Drug: Dexmedetomidine

  • Active comparator
    group B will receive Bupivacaine + Dexamethasone

    Patients will receive Bupivacaine 0.125% at 0.5 ml/kg + Dexamethasone 0.2 mg/kg for post operative analgesia.

    Drug: Dexamethasone

Interventions

  • as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia

  • as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia

06

What researchers measure

Primary outcomes

  1. duration of postoperative analgesia

    FLACC scale (Face, Leg, Activity, Crying, Consolability) total score of 0-10 ,so the duration of analgesia will be defined as the time from caudal injection to the point when FLACC score exceeds 4.

    Time frame: "Pain scores will be assessed at 15-minute intervals during the first two hours postoperatively, then at 4, 6, 8,12 and 24 hour"

Secondary outcomes

  1. Pain score

    Postoperative pain will be evaluated using the FLACC scale (Face, Leg, Activity, Crying, Consolability). Pain scores will be assessed at 15-minute intervals during the first two hours postoperatively, then at 4, 6, 8,12 and 24 hour. The duration of analgesia will be defined as the time from caudal injection to the point when FLACC score exceeds 4, at which time rescue analgesia is needed

    Time frame: "Pain scores will be assessed at 15-minute intervals during the first two hours postoperatively, then at 4, 6, 8,12 and 24 hour"

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.

Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 6 months is below that.

Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 9, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Dec 15, 2025
CompletionEst.
Dec 15, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07056244
Lead sponsor
Sohag University
Responsible party
Reham Ragab Younis (Resident-Anesthesia, ICU and pain management department-sohag hospital university, Sohag University) — Principal investigator
First posted
Jul 9, 2025
Start date
Jun 13, 2025
Primary completion
Dec 15, 2025 (estimated)
Completion
Dec 15, 2025 (estimated)
Last update
Aug 11, 2025

Study contacts

Reham R Younis, resident
Contact
reham_ragab_post@med.sohag.edu.eg
01113405849
Hala M Hashem, assistant professor
Contact
01004385249

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Dexamethasone

Start the discussion